Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person23
Fortress Biotech, Inc.
Company
Edesa Biotech, Inc.
Company
NKGen Biotech, Inc.
Company
XBiotech Inc.
Company
Krystal Biotech, Inc.
Company
New Fortress Energy Inc.
Company
Moleculin Biotech, Inc.
Company
GOLDENWELL BIOTECH, INC.
Company
ONCOLYTICS BIOTECH INC
Company
PharmaCyte Biotech, Inc.
Company
ESS Tech, Inc.
Company
Forte Biosciences, Inc.
Company
Vir Biotechnology, Inc.
Company
Sana Biotechnology, Inc.
Company
Fortis Inc.
Company
MAIA Biotechnology, Inc.
Company
PUMA BIOTECHNOLOGY, INC.
Company
Fort Technology Inc
Company
FDCTECH, INC.
Company
Fortrea Holdings Inc.
Company
Boundless Bio, Inc.
Company
TRex Bio, Inc.
Company
Fortinet, Inc.
Company
Primary record6
Fortress Biotech, Inc. filed SCHEDULE 13G/A
0001104659-26-120284.txt : 20261029 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001319244 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 09/30/2026 0001429260 Fortress Biotech, Inc. 34960Q307 1111 Ka
Quince Therapeutics, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Officers As previously announced, effective as
Fortress Biotech, Inc. filed 4
SEC form 4 filed by Fortress Biotech, Inc. (CIK 1429260) on 2026-10-01.
Fortress Biotech, Inc. filed 8-K
Item 8.01. Other Events. As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the Company ), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and Fe
Fortress Biotech, Inc. filed SCHEDULE 13G
0001104659-26-104386.txt : 20260901 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001319244 XXXXXXXX LIVE Common Stock, par value $0.001 per share 08/26/2026 0001429260 Fortress Biotech, Inc. 34960Q307 1111 Kane Con
Fortress Biotech, Inc. filed 8-K
Item 2.02. Results of Operations and Financial Condition . On August 13, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the quarter ended Jun